Palonosetron hydrochloride LA is under clinical development by LP Pharmaceutical (Xiamen) and currently in Phase III for Chemotherapy Induced Nausea and Vomiting. According to GlobalData, Phase III drugs for Chemotherapy Induced Nausea and Vomiting have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Palonosetron hydrochloride LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Palonosetron hydrochloride LA overview
Palonosetron hydrochloride is under development for the treatment of chemotherapy induced nausea and vomiting. The drug candidate targets 5HT3 receptor. It is a long acting preparation, administered through intravenous route as solution and buccal route as film.
LP Pharmaceutical (Xiamen) overview
LP Pharmaceutical (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
For a complete picture of Palonosetron hydrochloride LA’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
